According to filings with the U.S. Securities and Exchange Commission, Ordaos is raising up to $4,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, David Longo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ordaos
Ordaos is a human-enabled, machine-driven drug design company. Our miniPRO proteins help drug hunters deliver treatments that are safer and more effective than traditional discovery methods. For each client, we create billions of proteins and evaluate their properties in silico to reliably and repeatedly deliver the de novo mini-proteins that drug hunters only dream of. We then prove our consistency and unparalleled efficacy by rigorously synthesizing and testing top-ranking sequences in vitro. The result is a class of mini-proteins that threaten to revolutionize the role of proteins in drug discovery. The Ordaos Design Engine is a generative perception engine that leverages reinforcement learning and proprietary data sets to translate human-targeted product criteria into machine-designed mini-proteins. The design engine produces proteins that are more therapeutically effective, less likely to cause adverse side effects, and are easier and less expensive to develop, test, and manufacture than traditional proteins.

To learn more about Ordaos, visit http://ordaos.bio/
Ordaos Linkedin Page: https://www.linkedin.com/company/ordaosbio/

Contact:
David Longo, Chief Executive Officer
201-696-5358
https://www.linkedin.com/in/david-j-longo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.